Abbott Laboratories $ABT Shares Sold by Shell Asset Management Co.

Shell Asset Management Co. trimmed its stake in Abbott Laboratories (NYSE:ABT) by 90.6% in the third quarter, HoldingsChannel.com reports. The fund owned 10,818 shares of the healthcare product maker’s stock after selling 104,215 shares during the quarter. Shell Asset Management Co.’s holdings in Abbott Laboratories were worth $1,449,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Charles Schwab Trust Co raised its stake in shares of Abbott Laboratories by 109.8% in the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after buying an additional 19,966 shares in the last quarter. Nordea Investment Management AB lifted its holdings in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after buying an additional 18,974 shares during the last quarter. AE Wealth Management LLC grew its position in shares of Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after acquiring an additional 11,264 shares in the last quarter. Finally, iA Global Asset Management Inc. increased its holdings in shares of Abbott Laboratories by 94.0% in the 3rd quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock valued at $19,296,000 after acquiring an additional 69,803 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABT. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Argus cut their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Royal Bank Of Canada lowered their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Stock Performance

ABT opened at $112.63 on Monday. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a market cap of $195.84 billion, a PE ratio of 30.28, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. The business’s 50 day moving average is $119.48 and its 200-day moving average is $126.39.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.